Data Sheet (Cat.No.T6891)



MK-4101

Chemical Properties


CAS No.: 935273-79-3

Formula: C24H24F5N5O

Molecular Weight: 493.47

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

| Description | MK-4101, an effective inhibitor of the Hedgehog pathway, has anti-tumor activity through the induction of extensive apoptosis and inhibition of proliferation in tumor cells. | | |
|---------------|---|--|--|
| Targets(IC50) | Apoptosis,Hedgehog/Smoothened,Smo | | |
| In vitro | MK-4101 inhibits Hh signaling with an IC50 of 1.5 μ M in a reporter gene assay (Gli_Luc) in an engineered mouse cell line and 1 μ M in human KYSE180 esophageal cancer cells. It displaces a fluorescently-labeled cyclopamine derivative from 293 cells expressing recombinant human SMO with an IC50 of 1.1 μ M. MK-4101 arrests cells in G1 and G2 phases[1]. | | |
| In vivo | MK-4101 has robust antitumor activity through the inhibition of proliferation and induction of extensive apoptosis in tumor cells. MK-4101 is highly efficacious against primary medulloblastoma and basal cell carcinoma(BCC) developing in the cerebellum and skin of Ptch1+/- mice. Pharmacokinetics of MK-4101 shows that it could be administered orally, showing a good bioavailability ($F \ge 87$ %) with low-to-moderate plasma clearance in mice and rats. Moreover, it was well absorbed, and mainly excreted into the bile[1]. | | |
| Kinase Assay | Luciferase assays: After various compound treatments, cells are lysed in luciferase lysis buffer and assayed for luciferase activity using the ONE-Glo luciferase assay system. All luciferase activities are normalized to protein concentration determined by Bradford assay. | | |
| Cell Research | BCC cells are treated with MK-4101(10 μ M) for 72 h and cell cycle is analyzed by FACS monitoring EdU incorporation. (Only for Reference) | | |

Solubility Information

| Solubility | Ethanol: 60 mg/mL (121.59 mM), Sonication is recommended. |
|------------|---|
| | DMSO: 92 mg/mL (186.43 mM),Sonication is recommended. |
| | H2O: < 1 mg/mL (insoluble or slightly soluble), |
| | (< 1 mg/ml refers to the product slightly soluble or insoluble) |

Page 1 of 2 www.targetmol.com

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 2.0265 mL | 10.1323 mL | 20.2647 mL |
| 5 mM | 0.4053 mL | 2.0265 mL | 4.0529 mL |
| 10 mM | 0.2026 mL | 1.0132 mL | 2.0265 mL |
| 50 mM | 0.0405 mL | 0.2026 mL | 0.4053 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Filocamo G, et al. Mol Cancer Ther. 2016, 15(6):1177-89.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481

Page 2 of 2 www.targetmol.com